Caixa Capital Risc leads €1.5m round for Iproteos

The company aims to use the capital injection to boost the regulatory pre-clinical trial for the company's schizophrenia-dedicated drug treatment and subsequently start the first phase of trials on patients. After the approval from tests in humans, the company aims to license the drug to a large pharmaceutical corporate to complete its development.

Previous funding
Following the round, the company has raised a total of €3m in funding since its foundation in 2011. Prior to the deal, the business had raised €1.5m in June 2016. As part of the injection, an unnamed biotech-dedicated venture capital fund provided €1m in equity, while Spanish state-backed investing agency Enisa provided €250,000 and the crowdfunding platform Capital Cell the remainder.

Company
Established in 2011, Iproteos span out from the University of Barcelona and develops therapeutic molecules, named peptiomimetics, focusing on drug treatments for schizophrenia, epilepsy and atherosclerosis.

People
Kinled Holding – Patrick Aisher (chair).
Iproteos – Teresa Tarragó (co-founder, CEO); Ernest Giralt (co-founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Venture
• Spain
• Caixa Capital Risc